Related Experiment Videos

Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma

N L Dorward1, R A Hawkins, I R Whittle

  • 1Department of Clinical Neurosciences, Western General Hospital, Edinburgh, Scotland.

British Journal of Neurosurgery
|January 1, 1993
PubMed

Insights

Epidermal growth factor receptor (EGF-r) activity did not correlate with survival or age in glioblastoma patients. Similarly, EGF-r levels in meningioma patients showed no relation to outcome, suggesting routine testing is not beneficial.

Area of Science:

  • Neuro-oncology
  • Molecular biology
  • Clinical research

Background:

  • Glioblastoma multiforme (GBM) and meningioma are primary brain tumors.
  • Epidermal growth factor receptor (EGF-r) is implicated in cancer development.
  • The role of EGF-r activity in GBM and meningioma prognosis requires further clarification.

Purpose of the Study:

  • To investigate the relationship between EGF-r activity and clinical outcomes in patients with GBM and meningioma.
  • To determine if EGF-r activity can serve as a prognostic biomarker for these intracranial tumors.

Main Methods:

  • Retrospective analysis of EGF-r activity in tumor samples from GBM (n=27) and meningioma (n=18) patients.
  • Correlation of EGF-r activity with patient survival time, age, and clinical outcome post-surgery.

Main Results:

  • No significant association was found between EGF-r activity and survival time or age in GBM patients.
  • EGF-r activity in meningioma patients did not correlate with age or clinical outcome at a median follow-up of 40 months.

Conclusions:

  • Routine estimation of EGF-r activity is not indicated for GBM and meningioma patients.
  • EGF-r activity does not appear to be a reliable prognostic indicator for these brain tumors.

Related Concept Videos